Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference 2024
20 slides from Crinetics Pharmaceuticals's conference presentation, Jan 8, 2024
Slide 1: 42nd Annual J.P. Morgan Healthcare Conference
Exhibit 99.1 nd 42 Annual J.P. MORGAN Healthcare Conference JA NUA RY 9 , 2 02 4
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” or “our”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These
Slide 3: Building a Premier Fully Integrated Endocrine-focused Pharmaceutical Company
Building a Premier Fully Integrated Endocrine- focused Pharmaceutical Company Strategic Approach to Growing Long-term Value 3
Slide 4: 2023 Laid the Foundation for a Transformative 2024-2025
Positive Phase 3 Results in Acromegaly for Paltusotine 2023 Laid the Foundation for a Positive Initial Phase 2 Results in Carcinoid Syndrome for Paltusotine Transformative Completed Enrollment in Second Phase 3 Study for 2024-2025 Acromegaly Initiated Two Phase 2 Studies for Second Clinical Asset (C
Slide 5: The Crinetics Way: Endocrinology for Health
The Crinetics Way: Endocrinology for Health Deep roots in endocrinology Purposely crafted Commitment to transforming = people’s lives medicines World-class in-house R&D Paltusotine is an investigational drug candidate currently in clinical studies 5 |
Slide 6: Deep Pipeline of Transformative Drug Candidates
Deep Pipeline of Transformative Drug Candidates Discovery Preclinical Phase 1 Phase 2 Phase 3 Program Anticipated Milestones Acromegaly (PATHFNDR-1) NDA Submission (2H24) Acromegaly (PATHFNDR-2) Paltusotine (SST2 agonist) Topline Results (1Q24) Full Phase 2 Data Release (1H24) Carcinoid syndrome Cus
Slide 7: Paltusotine: Lead Clinical Asset for Acromegaly and Carcinoid Syndrome
World-class Development Leading to Global Commercialization Paltusotine: Lead Clinical Asset for Acromegaly and Carcinoid Syndrome PATHFNDR-1 CARCINOID SYNDROME PHASE 3 RESULTS PHASE 2 RESULTS 7
Slide 8: Paltusotine: Designed to Allow People with Acromegaly and Carcinoid Syndrome to Focus on Living
Paltusotine: Designed to Allow People with Acromegaly and Carcinoid Syndrome to Focus on Living POTENTIAL CURRENT STANDARD BENEFITS OF Reliable, Poor PALTUSOTINE* OF CARE consistent, Symptom and durable Control control 77% report No injection injections, VS site well reactions tolerated Painful, inc
Slide 9: Positive Phase 3 Results in Acromegaly Provide Strong Footing for First Commercial Launch in 2025
Positive Phase 3 Results in Acromegaly Provide Strong Footing for First Commercial Launch* in 2025 100% 83% (25/30) p<0.0001 80% SECONDARY ENDPOINTS PRIMARY ENDPOINT SAFETY (paltusotine arm vs placebo) 60% 83% of participants Change from baseline in Paltusotine was well- on paltusotine IGF-1 (p < 0.
Slide 10: Paltusotine: Progressing Towards Phase 3 in a Second, More Prevalent Indication
Paltusotine: Progressing Towards Phase 3 in a Second, More Prevalent Indication 5-HT + Other Carcinoid Syndrome Lung Factors ~33,000 Patients Diagnosed with Carcinoid Syndrome (US) Facial flushing in a patient with carcinoid syndrome NETs Treatment Goals 1. Reduce frequency and urgency of highly dis
Slide 11: Example Carcinoid Syndrome Study Participant: Elimination of Flushing and Normalization of BMs
Example Carcinoid Syndrome Study Participant: Elimination of Flushing and Normalization of BMs 10 9 8 Paltusotine 80 mg/day 7 Excess BM 6 >3/d BMs Flushes 5 4 3 No Prior 2 Normal BM Therapy 3/d to 3/w 1 0 -1 -30 -20 -10 0 10 20 30 40 50 60 Study Day 11 BM = bowel movement Frequency (per day)
Slide 12: Paltusotine Reduced the Frequency of Both Key Carcinoid Syndrome Core Symptoms
Paltusotine Reduced the Frequency of Both Key Carcinoid Syndrome Core Symptoms: Excess BM and Flushing Flushing Frequency Excess Bowel Movement* Frequency For Patients with ≥1/day at Baseline For Patients with >3/day at Baseline 3.0 p < 0.01 p = 0.05 3.0 N=19 N=11 3.1 2.0 -65% 2.0 -65% 2.3 1.0 1.0 1
Slide 13: Paltusotine: Initial Multi-billion Dollar U.S. Market Opportunity in Acromegaly and Carcinoid Syndrome
Paltusotine: Initial Multi-billion Dollar U.S. Market Opportunity in Acromegaly and Carcinoid Syndrome Acromegaly Carcinoid Syndrome Diagnosed Prevalence 27,000 33,000 (U.S. Patients) Addressable Patients 11,000 33,000 Not cured surgically Candidates for SRL Current Patients 10,000 10,000 On Endocri
Slide 14: Building the Base for Commercial Success in Multiple Indications for Paltusotine
CONFIDENTIAL Building the Base for Commercial Success in Multiple Indications for Paltusotine Complete Prescribers Map Market Research • 200 HCPs initiating 80% of • Backbone of marketing group acromegaly scripts in place • 40 overlapping centers for both • Market research indicates pituitary and NC
Slide 15: World-class Discovery to Grow the Clinical Pipeline
World-class Discovery to Grow the Clinical Pipeline World-class Discovery to Grow the Clinical Pipeline Following the Crinetics way to create medicines to help increasingly larger numbers of people 15
Slide 16: CRN04894: Second Clinical Asset In Late-Stage Development
CRN04894: Second Clinical Asset In Late-Stage Development Skillfully Crafted to Help Patients Reach Their Treatment Goals Stress Hypothalamus Lead Indication: Congenital Adrenal Hyperplasia (CAH) Circadian ~27,000 Patients Prevalent/Diagnosed with Classical CAH (US) CRF CRF Clock AVP AVP Treatment G
Slide 17: CRN04894: Targeting Mechanism Designed to Provide Maximum A4 Suppression
CRN04894: Targeting Mechanism Designed to Provide Maximum A4 Suppression. Initial Data Expected 2Q24 A4 suppression and steroid sparing expectations for different mechanisms of action in CAH Patients 700 on Glucocorticoids 600 Mean CRF 500 Dependent A4 Expected ACTH 400 Patients GC dose reduction De
Slide 18: Two New Programs Anticipated to Begin First-in-human Enabling Studies in 2024
Two New Programs Anticipated to Begin First-in-human Enabling Studies in 2024 PTH Antagonist for Hyperparathyroidism TSH Antagonist for Graves’ Disease and TED* Vehicle Vehicle Vehicle or or or Antagonist Antagonist Antagonist PO PO PO 2.0 1.8 Vehicle 3 mg/kg antagonist M22 Vehicle agonist 10 mg/kg
Slide 19: Building a Premier Fully Integrated Endocrine-focused Pharmaceutical Company
Building a Premier Fully Integrated Endocrine-focused Pharmaceutical Company • 1H Commence CAH Phase 3 • 2H Paltusotine acromegaly ** ** PDUFA and launch • Human POC from new drug • 2H File Acromegaly NDA candidates • 2Q Initial Phase 2 data • New drug candidates enter readouts in CAH and • Multiple
Slide 20: Thank You
?Crinetics Thank You
Crinetics Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix